The TASTE-2 study was a multicenter, double-blind, randomized, placebo-controlled trial that assessed the efficacy and safety of edaravone dexborneol in patients with acute ischemic stroke undergoing endovascular thrombectomy. Patients aged 18-80 years with symptoms within 24 hours, NIHSS score 6-25 and ASPECTS 6-10 with large vessel occlusion were included; 690 received edaravone dexborneol (30 mg edaravone + 7.5 mg (+)-dexborneol) and 672 placebo twice daily for 10-14 days. The primary endpoint was functional independence at 90 days as measured by a modified Rankin score of 0-2. Of the 1360 patients analyzed, 55.0% (379/689) achieved independence in the edaravone dexborneol group versus 49.6% (333/671) in the placebo group (hazard ratio 1.11, 95% CI 1.02-1.20; hazard difference 5.4%, 95% CI 0.1-10.7%). In the subgroup with discordance at admission (NIHSS ≥10 and ASPECTS ≥9 or NIHSS ≥20 and ASPECTS ≥7), independence was 55.5% (178/321) versus 42.9% (134/312), hazard ratio 1.29 (95% CI 1.06-1.58; P interaction=0.003). The incidence of serious adverse events was similar (27.2% vs. 25.7%, hazard ratio 1.06, 95% CI 0.89-1.26). The study suggests a higher probability of functional independence at 90 days in patients treated with edaravone dexborneol safely without risk, especially in the nonadherent subgroup.